Last reviewed · How we verify
Intra-Arterial Albumin
Intra-Arterial Albumin is a Plasma protein/colloid Small molecule drug developed by Tianjin Huanhu Hospital. It is currently in Phase 3 development for Acute organ ischemia or hypoperfusion (indication under investigation in Phase 3).
Intra-arterial albumin administration increases plasma oncotic pressure and improves microcirculation to enhance tissue perfusion and organ function.
Intra-arterial albumin administration increases plasma oncotic pressure and improves microcirculation to enhance tissue perfusion and organ function. Used for Acute organ ischemia or hypoperfusion (indication under investigation in Phase 3).
At a glance
| Generic name | Intra-Arterial Albumin |
|---|---|
| Sponsor | Tianjin Huanhu Hospital |
| Drug class | Plasma protein/colloid |
| Modality | Small molecule |
| Therapeutic area | Critical Care / Organ Perfusion |
| Phase | Phase 3 |
Mechanism of action
Albumin is a natural plasma protein that maintains colloid osmotic pressure, preventing fluid extravasation from the intravascular space into tissues. When administered intra-arterially, it directly increases local blood viscosity and oncotic pressure in target organs, improving perfusion and reducing edema. This mechanism is thought to enhance oxygen delivery and metabolic function in ischemic or hypoperfused tissues.
Approved indications
- Acute organ ischemia or hypoperfusion (indication under investigation in Phase 3)
Common side effects
- Hypervolemia
- Pulmonary edema
- Allergic reaction
- Infection risk
Key clinical trials
- Yttrium Y-90 Radioembolization in Treating Patients With Metastatic Liver Cancer (PHASE1)
- Efficacy and Safety of Intra-Arterial Albumin as Adjunct to Mechanical Thrombectomy in Acute Ischemic Stroke (PHASE2)
- The Preliminary Efficacy and Safety of Intra-Arterial Albumin as Adjunct to Mechanical Thrombectomy in Acute Ischemic Stroke (PHASE2)
- Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC (PHASE3)
- Intra-arterial Albumin Infusion After Endovascular Therapy for Stroke Patients (PHASE1)
- Safety Study of Radio-labeled huA33 Antibody in Colorectal Cancer (NA)
- CPB Prime Fluid Strategies to Preserve Mcirocirculatory Perfusion (NA)
- Intra-arterial Chemotherapy Combined with Radiotherapy and Immunotherapy for HNSCC (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intra-Arterial Albumin CI brief — competitive landscape report
- Intra-Arterial Albumin updates RSS · CI watch RSS
- Tianjin Huanhu Hospital portfolio CI
Frequently asked questions about Intra-Arterial Albumin
What is Intra-Arterial Albumin?
How does Intra-Arterial Albumin work?
What is Intra-Arterial Albumin used for?
Who makes Intra-Arterial Albumin?
What drug class is Intra-Arterial Albumin in?
What development phase is Intra-Arterial Albumin in?
What are the side effects of Intra-Arterial Albumin?
Related
- Drug class: All Plasma protein/colloid drugs
- Manufacturer: Tianjin Huanhu Hospital — full pipeline
- Therapeutic area: All drugs in Critical Care / Organ Perfusion
- Indication: Drugs for Acute organ ischemia or hypoperfusion (indication under investigation in Phase 3)
- Compare: Intra-Arterial Albumin vs similar drugs
- Pricing: Intra-Arterial Albumin cost, discount & access